Examples of using Ucb in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
About UCB.
BASF and UCB v Commission.
George worked for UCB Inc.
However, UCB did not accept.
I took a class at UCB.
EIB supporting UCB RD programme.
In this context, UCB also announces that, after close to 13 years in the role, the company's Chief Financial Officer, Detlef Thielgen, will be transitioning out within a year from now.
Blue, oblong, scored and debossed with the code“ ucb” and“ 250” on one side.
During July, UCB has successfully produced over 180 tonne of 700mm dia(27.6" diam) in both flake and nodular grades, yet another world record, with much of it sold on pre orders.
APPSfactory developed an application on behalf of UCB Pharma GmbH that assists epilepsy patients with everyday activities.
UCB Pharma Ltd, Unit 11- 14 Foster Avenue, Woodside Park, Dunstable, Bedfordshire LU5 5TA, United Kingdom UCB Pharma Ltd, 208 Bath Road, Slough, Berkshire SL1 3WE, United Kingdom.
 Version 2.0 of the Epi-Manager,an app specially created for epilepsy patients on behalf of UCB Pharma, offers users a range of new features that can assist them in coping with everyday challenges.
When the Upright Citizens Brigade relocated to New York from Chicago in 1996, Daly was one of the first New Yorkers to study improvisation with the group andperformed in many of the earliest shows produced by the UCB.
In this respect, the Commission notes that in 2003, the most recent financial year preceding this Decision,the turnover of UCB was EUR 3 billion, that of Akzo Nobel EUR 13 billion and that of BASF EUR 33,4 billion.
In March, UCB announced the approval of Cimzia®(certolizumab pegol) in the U.S. to include a new indication for the treatment of adults with active non-radiographic axial spondyloarthritis(nr-axSpA) with objective signs of inflammation.
We're happy that our cutting-edge research and innovation is yet again recognized by the EIB, and that they have chosen UCB as a first partner for their new“at-risk co-development funding” approach.
UCB undertook to supply Almirall in a regular fashion with its entire requirements of Piracetam, and Almirallundertook to purchase a high fixed percentage(declining over a period of three years) of its total requirementsfrom UCB.
Therefore, at the time of the withdrawal,the CHMP' s view was that a benefit of Lacosamide Pain UCB Pharma had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.
On 25 September 2008, UCB Pharma S. A. officially notified the Committee for Medicinal Products for Human Use(CHMP) that it wishes to withdraw its application for a marketing authorisation for Lacosamide Pain UCB Pharma, for the treatment of diabetic neuropathic pain in adults.
At global level, four North American producers and the European producers Akzo Nobel,BASF and UCB participated in anti-competitive activities having as their purpose the allocation of worldwide markets between June 1992 and April 1994.
Brussels-based UCB is a global biopharmaceutical company dedicated to researching and developing innovative drugs and treatment options for immune and inflammatory illnesses and the central nervous system to improve the quality of life for people with severe diseases.
Pending the effectiveness of national efforts to successfullylink our education system to the LMD system, UCB training lasts another five(5) years, including three(3) years of Graduate and two(2) years of License.
E Commission imposed the following nes on the European producers: EUR 20.99 million jointly and severally on Akzo Nobel NV, Akzo Nobel Nederland BV, Akzo Nobel Chemicals International BV, Akzo Nobel Chemicals BV and Akzo Nobel Functional Chemicals BV,EUR 34.97 million on BASF AG and EUR 10.38 million on UCB SA.
Four North American producers,and five companies in the Akzo Nobel group plus BASF AG and UCB SA, participated in anti-competitive activities having as their purpose the allocation of worldwide markets between June 1992 and April 1994.
UCB, a leading Belgian chemical and pharmaceutical producer, notified to the Commission a supply agreementcovering in particular Piracetam, the active ingredient for a class of vasodilator, psychotropic and nootropic pharmaceuticals, that it had concluded with Almirall, a Spanish pharmaceutical manufacturer and the most important Piracetam-purchaser in Europe.
Other members of the committee were Bob Fabry,Bill Joy and Sam Leffler from UCB, Alan Nemeth and Rob Gurwitz from BBN, Dennis Ritchie from Bell Labs, Keith Lantz from Stanford, Rick Rashid from Carnegie-Mellon, Bert Halstead from MIT and Dan Lynch from ISI.
On 9 December, the Commission adopted a decision finding against Akzo Nobel NV, Akzo Nobel Nederland BV, Akzo Nobel Chemicals International BV, Akzo Nobel Chemicals BV and Akzo Nobel Functional Chemicals BV, jointly and severally, Chinook Group Limited Partnership and Chinook Group Limited, jointly and severally, BASF AG, Bioproducts Incorporated,DuCoa LP and UCB SA.
In accordance with the Code of Canon Law, in its canons 807 to 814 and the Apostolic Constitution Ex Corde Ecclesiae of 15 August 1990 relating to Catholic universities andhigher institutes, UCB Shines through its training to the overarching social objectives in a Region of Kivu, With a network of secondary schools providing the best of its students.
At a launch event in Brussels today, the private partners were represented by: Roch Doliveux,CEO of UCB, Henri Winand, CEO of Intelligent Energy, Jean-Paul Herteman, Chairman and CEO of the Safran Group, Peder Holk Nielsen, CEO of Novozymes, Jean-Marc Chery, Chief Operating Officer of STMicroelectronics, Jochen Eickholt, CEO of Divison Rail Systems, Siemens AG, Infrastructure Cities Sector, and Massimo Garbini, CEO of ENAV.